An antigen peptide combination associated with breast cancer driver gene mutation and its application
By developing a combination of antigen peptides related to breast cancer driver gene mutation with high MHCI molecular affinity, specific CTLs are activated, and the problem of poor breast cancer treatment in the prior art is solved, and effective immune clearance and prevention of breast cancer cells is achieved. .
Patent Information
- Application Number
- CN202111303468.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-03-24
- Filing Date
- 2021-05-28
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-05-28
AI Technical Summary
The prior art has failed to systematically discover and establish a library of antigen peptides related to breast cancer driver gene mutations, resulting in poor treatment effects of breast cancer and multiple complications.
Develop an antigen peptide combination associated with mutations in breast cancer driver genes, which has a high MHCI molecular affinity and is able to stimulate and induce the production of specific cytotoxic T lymphocytes (CTLs) for inducing the immune system to clear tumor cells, and prepare A therapeutic agent for preventing and interfering with the risk of breast cancer.
Through high-throughput gene sequencing and data analysis, individualized antigen peptide combinations are screened, activate T cells to recognize and kill mutant tumor cells, inhibit tumor growth, significantly improve the prevention and treatment effect of breast cancer, and have good clinical transformation and disease Prevention prospects.
Smart Images

Figure BDA0003339260160000041
Abstract
Description
[0001] This application is a divisional application of application number 202110592054.1, application date May 28, 2021, and invention name “An antigen peptide associated with breast cancer driver gene mutation and its application”. Technical Field
[0002] The present invention relates to an antigen peptide combination related to breast cancer driver gene mutation and application thereof, belonging to the technical field of biomedicine. Background Art
[0003] Breast cancer has become a major public health issue in today's society. The cause of breast cancer is not yet fully understood, but studies have found that there is a certain regularity in the onset of breast cancer, and women with high-risk factors for breast cancer are more likely to develop breast cancer. The so-called high-risk factors refer to various risk factors related to the onset of breast cancer.
[0004] The treatment of breast cancer mostly adopts a variety of methods such as surgery, radiotherapy, chemotherapy, endocrine therapy, biological targeted therapy and adjuvant therapy of traditional Chinese medicine. Surgery plays an important role in the diagnosis, staging and comprehensive treatment of breast cancer. Radiotherapy is the use of radiation to destroy the growth and reproduction of cancer cells, so as to control and eliminate cancer cells. Surgery and radiotherapy are both local treatments. Chemotherapy is a treatment method that uses anticancer drugs to inhibit the division of cancer cells and destroy cancer cells. It is referred to as chemotherapy. Endocrine therapy is the use of drugs or the removal of endocrine glands to regulate the endocrine function of the body and reduce the secretion of endocrine hormones, so as to achieve the purpose of treating breast cancer. However, although radiotherapy and chemotherapy can improve the long-term survival rate, there are many complications and the effect is unsatisfactory.
[0005] As people become more aware of the nature of tumor-driving gene mutations and personalized precise immune response reactions, personalized tumor-driving gene mutation-related peptide antigens have been proposed as a new concept for tumor-specific neoantigen immune cell therapy. Through the tumor's unique driver gene mutation-related antigens, the body's natural T cell immune defense system is induced to selectively destroy tumor gene mutation cells, thereby effectively preventing the occurrence of multiple cancers. This technical field has been rated as one of the top ten scientific and technological innovation research fields in the United States in 2019.
[0006] However, because the technology requires multidisciplinary, high-tech, and multi-platform collaborative research, the antigenic peptides associated with breast cancer driver gene mutations have not been systematically discovered and a relatively complete peptide library has not been established, so a therapeutic agent with superior effects has not yet been formed. Summary of the invention
[0007] In order to overcome the shortcomings of the prior art, the first purpose of the present invention is to provide an antigen peptide combination related to breast cancer driver gene mutations, which has a high affinity for the MHCI molecules on DC cells and can effectively stimulate and induce the production of specific cytotoxic T lymphocytes (CTLs), which can be used for immune clearance of tumor cells with breast cancer-related driver gene mutations and has good therapeutic potential.
[0008] The second object of the present invention is to provide an application of the above-mentioned antigen peptide combination associated with breast cancer driver gene mutation.
[0009] The first object of the present invention can be achieved by adopting the following technical scheme: an antigen peptide combination related to breast cancer driver gene mutation, the sequence of the antigen peptide combination is SEQ ID NO.4, SEQ ID NO.7, SEQ ID NO.10, SEQ ID NO.13, SEQ ID NO.15 and SEQ ID NO.17.
[0010] The second object of the present invention can be achieved by adopting the following technical scheme: an application of an antigen peptide combination associated with breast cancer driver gene mutations, wherein the antigen peptide combination associated with breast cancer driver gene mutations as described above is used to induce the production of specific cytotoxic T cell clones.
[0011] Or, an application of an antigen peptide combination associated with breast cancer driver gene mutations, wherein the antigen peptide combination associated with breast cancer driver gene mutations as described above is used to prepare a human immune activity regulator that can induce the production of specific cytotoxic T cell clones.
[0012] Or, an application of an antigen peptide combination associated with breast cancer driver gene mutations, wherein the antigen peptide combination associated with breast cancer driver gene mutations as described above is used to prepare a cell culture fluid for preventing and intervening in mutations of ESR1, GATA3, PALB2, SLC24A4, HAUS3 and KMT2C genes.
[0013] Or, an application of an antigen peptide combination associated with breast cancer driver gene mutations, using the antigen peptide combination associated with breast cancer driver gene mutations as described above to prepare a breast cancer risk intervention therapeutic agent.
[0014] The present invention conducts a comprehensive study based on a specific type of cancer, specifically studies the mechanism of breast cancer occurrence, and eliminates breast cancer cells with mutations in ESR1, GATA3, PALB2, SLC24A4, HAUS3 and KMT2C breast cancer driver genes, which can inhibit the growth of tumor cells and prevent the occurrence of breast cancer. Immunological studies have confirmed that the principle of CD8 positive T lymphocytes CTL to exert cellular immunity is that CTL cells are activated by recognizing antigen peptides bound to MHC-I molecules, and the activated CTL can kill the corresponding target cells and play an immune surveillance role.
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] 1. The antigen peptide combination (neoantigen) associated with breast cancer driver gene mutations of the present invention refers to antigen peptides expressed by tumor cells that can activate T cells; through high-throughput gene sequencing and data analysis, the patient's tumor is found to have many individual somatic mutations, and the antigen peptide combination associated with the driver gene mutation is screened out as a target, which is chemically synthesized in vitro and loaded onto antigen presenting cells (APCs), thereby activating T cells to recognize a variety of neoantigen peptides, thereby producing a therapeutic effect of killing mutated tumor cells;
[0017] 2. The antigen peptide combination related to breast cancer driver gene mutations screened by the present invention has a high affinity with MHC I molecules on DC cells and can effectively stimulate and induce the production of specific cytotoxic T lymphocytes (CTLs) to inhibit tumor cell growth, indicating that it has good potential for polypeptide vaccines and DC vaccines, and has good prospects for clinical transformation and disease prevention. DETAILED DESCRIPTION
[0018] Below, in conjunction with specific implementation modes, the present invention is further described:
[0019] The antigen peptides associated with breast cancer driver gene mutations used in the examples are shown in Table 1:
[0020] Table 1 Antigenic peptide sequences associated with breast cancer driver gene mutations
[0021]
[0022] The operation of establishing antigen peptide-specific CTL clones associated with breast cancer driver gene mutations is as follows:
[0023] 10 from the same healthy donor 5 CD8 + T cells were loaded with 10 antigenic peptides associated with breast cancer driver gene mutations 4 After stimulating Mo-DCs twice with an interval of 1 week, 105 The PBMCs were treated with mitomycin C and loaded with antigenic peptides associated with breast cancer driver gene mutations, and then screened by standard cytotoxicity assay.
[0024] T2 cells were loaded with 5uM antigen peptides associated with breast cancer driver gene mutations as target cells, and the antigen peptide-specific cytotoxicity of CTLs associated with breast cancer driver gene mutations was confirmed by LDH release assay.
[0025] LDH lactate dehydrogenase cytotoxicity assay:
[0026] 1) Adjust the target cells to 5×10 cells / mL using RPMI-1640 medium containing 5% fetal calf serum. 4 -2×10 5 / mL;
[0027] 2) Add target cells to a 96-well round-bottom cell culture plate, add 100 μL to each well. No target cells were added to the three effector cell natural release control wells, only 100 μL of culture medium was added;
[0028] 3) Add 100 μL of CTL effector cells (CD8+T cells) to each well, with the ratio of effector cells to target cells being 10:1; add 100 μL of culture medium to the natural release wells without adding effector cells, and add 100 μL of 1vt% NP40 to the maximum release wells. Set up three replicate wells for each experiment;
[0029] 4) Place in a carbon dioxide incubator at 37°C and 5vt% CO2 for 4-6 hours;
[0030] 5) Centrifuge the culture plate at 200×g for 10 min; aspirate 150 μL of supernatant from each well and add it to another 96-well ELISA plate; add 20 μL of 0.4 mol / L lactic acid solution, 20 μL of 4 mmol / L 2-p-iodophenyl-3-p-chloronitrophenyltetrazole, and 20 μL of reaction solution (PBS containing 0.03 vt% BSA, 2.7 U / mL lipoamide dehydrogenase, 4.5 mmol / L hydrogenated coenzyme I (NAD+), and 1.2 vt% sucrose) to each well of the second plate in sequence, and place at room temperature for 20 min;
[0031] 6) Measure the optical density (OD value) of each well on an enzyme-linked detector with a detection wavelength of 492 nm and a reference wavelength of 650 nm.
[0032] By adopting the above in vitro induction method for establishing antigen peptide-specific CTL clones associated with breast cancer driver gene mutations, the present invention also established MHC-I restricted CTL clones, and confirmed their peptide-specific immune response effects through IFN-γ release experiments.
[0033] IFN-γ release assay:
[0034] 1) Coating antibody: dilute 44 μL capture antibody and 12 mL coat buff at 1:250, coat each well of a 96-well ELISA plate with 100 μL of the above solution at 4°C overnight;
[0035] 2) Wash the plate 3 times, prepare washing solution, add 50mL of distilled water to make 1000mL of wash buff, dilute 1:20, and wash the plate 3 times with an automatic plate washer;
[0036] 3) Block each well with 220 μL assay dilution and place at room temperature for 1 hour;
[0037] 4) Wash the plate 3 times;
[0038] 5) Prepare standard samples, dilute in equal proportions, and establish a concentration gradient, namely blank well, 4.7pg / mL, 9.4pg / mL, 18.8pg / mL, 37.5pg / mL, 75pg / mL, 150pg / mL, 300pg / mL. Add the sample to be tested and the secondary well in sequence. If the concentration is too high, dilute it. Leave at room temperature for 2 hours;
[0039] 6) Wash the plate 5 times;
[0040] 7) Prepare detection antibody (secondary antibody) by adding 48μL detector antibody to 12mL assay dilution to make one solution. When adding the sample, add 48μL SAV-HRP to one solution immediately. Place 100μL in each well at room temperature for 1h.
[0041] 8) Wash the plate 7 times;
[0042] 9) Add the colorimetric substrate streptavidin peroxidase and incubate in dark for 30 min;
[0043] 10) Add the stop solution and perform colorimetry on a microplate reader using 450 nm as the measurement wavelength and 620 nm as the reference wavelength to prepare a standard curve.
[0044] The results are shown in Table 2, which are the experimental data of IFN-γ release of antigen peptides of SEQ ID NO.1-18, with PBS phosphate buffer and negative control peptide (the control peptide sequence is shown in SEQ ID NO.19 as: AAAAAAAAA) as controls, and the experimental results are absorbance values. The above experimental data show that the CTL epitope established by the present invention is extremely effective, and the predicted results are in very good agreement with the experimental results.
[0045] Table 1 Antigen peptide IFN-γ release test results (absorbance value)
[0046] Serial number Antigenic peptide PBS control Negative control SEQ ID NO.1 485 32 36 SEQ ID NO.2 479 32 37 SEQ ID NO.3 469 30 38 SEQ ID NO.4 472 31 39 SEQ ID NO.5 473 34 40 SEQ ID NO.6 475 33 39 SEQ ID NO.7 478 32 38 SEQ ID NO.8 485 32 37 SEQ ID NO.9 483 32 36 SEQ ID NO.10 469 32 35 SEQ ID NO.11 468 32 34 SEQ ID NO.12 467 32 35 SEQ ID NO.13 465 32 36 SEQ ID NO.14 471 30 37 SEQ ID NO.15 472 30 38 SEQ ID NO.16 479 30 39 SEQ ID NO.17 475 30 40 SEQ ID NO.18 476 30 41
[0047] Combination of at least two antigenic peptides:
[0048] Combination 1: SEQ ID NO.3, SEQ ID NO.7, SEQ ID NO.13 and SEQ ID NO.17;
[0049] Combination 2: SEQ ID NO.10 and SEQ ID NO.17;
[0050] Combination 3: SEQ ID NO.4, SEQ ID NO.7, SEQ ID NO.10, SEQ ID NO.13, SEQ ID NO.15 and SEQ ID NO.17;
[0051] The above three antigen peptide combinations were used to perform IFN-γ release experiments, with PBS phosphate buffer and negative control peptide (the control peptide sequence is shown in SEQ ID NO.19: AAAAAAAAA) as controls. The experimental results are absorbance values, and the results are shown in Table 3.
[0052] Table 3 IFN-γ release test results of antigen peptide combination (absorbance value)
[0053] combination Antigenic peptide PBS control Negative control Combination 1 623±18 28±2 39±3 Combination 2 635±35 29±1 38±3 Combination 3 610±14 32±1 39±5
[0054] It can be seen that by presenting at least two of the above-mentioned breast cancer driver gene mutation-related antigenic peptides through dendritic cells and co-culturing with cytotoxic lymphocyte T cells, antigen peptide-specific cytotoxic T lymphocytes can be induced and screened. Such antigen-specific cytotoxic T lymphocytes can be used for immune clearance of tumor cells with breast cancer-related driver gene mutations and prevention of the occurrence of related diseases, especially tumor diseases.
[0055] At least two of the above antigenic peptides are loaded and re-infused into dendritic cells (DCs), which can be used as DC vaccines for disease prevention, stimulating the body to produce peptide-specific anti-cytotoxic T cells related to breast cancer driver gene mutations, thereby achieving the prevention of diseases related to breast cancer driver gene mutations.
[0056] The antigen peptide combination associated with breast cancer driver gene mutations of the present invention is short in length and easy to chemically synthesize. A high-purity product can be directly synthesized, which greatly reduces the application cost. At the same time, the effect is clear and has great application potential.
[0057] For those skilled in the art, various other corresponding changes and modifications can be made according to the technical solutions and concepts described above, and all of these changes and modifications should fall within the protection scope of the claims of the present invention. SEQUENCE LISTING <110> Shenzhen New Targeted Biotechnology Co., Ltd. <120> An antigen peptide combination associated with breast cancer driver gene mutation and its application <130> 2021 <160> 19 <170> PatentIn version 3.5 <210> 1 <211> 9 <212> PRT <213> Artificial Sequence <400> 1 Phe Thr Asp Tyr Glu Leu Lys Ala Tyr 1 5 <210> 2 <211> 9 <212> PRT <213> Artificial Sequence <400> 2 Ser Glu Met Ile Lys Phe Ala Ser Tyr 1 5 <210> 3 <211> 10 <212> PRT <213> Artificial Sequence <400> 3 Ser Thr Ser Ser His Ser Leu Gln Lys Tyr 1 5 10 <210> 4 <211> 10 <212> PRT <213> Artificial Sequence <400> 4 Met Ser Asn Lys Gly Met Glu His Leu Tyr 1 5 10 <210> 5 <211> 9 <212> PRT <213> Artificial Sequence <400> 5 Leu Pro Glu Glu Val Asp Val Leu Phe 1 5 <210> 6 <211> 10 <212> PRT <213> Artificial Sequence <400> 6 Leu Pro Glu Glu Gly Asp Val Leu Phe Glu 1 5 10 <210> 7 <211> 11 <212> PRT <213> Artificial Sequence <400> 7 Leu Trp Arg Arg Asp Gly Thr Gly His Tyr Leu 1 5 10 <210> 8 <211> 11 <212> PRT <213> Artificial Sequence <400> 8 Lys Arg Arg Leu Ser Ala Ala Arg Arg Ala Gly 1 5 10 <210> 9 <211> 9 <212> PRT <213> Artificial Sequence <400> 9 Ser Pro Ala Lys Pro His Thr Thr Leu 1 5 <210> 10 <211> 9 <212> PRT <213> Artificial Sequence <400> 10 Ala Glu Leu Pro Ala Ser Asp Ser Ile 1 5 <210> 11 <211> 9 <212> PRT <213> Artificial Sequence <400> 11 Phe Pro Glu Ala Gly Leu Arg Ile Met 1 5 <210> 12 <211> 10 <212> PRT <213> Artificial Sequence <400> 12 Ser Glu Leu Glu Pro Glu Ala Asn Asp Phe 1 5 10 <210> 13 <211> 9 <212> PRT <213> Artificial Sequence <400> 13 Phe Pro Glu Ala Asn Asp Arg Ile Met 1 5 <210> 14 <211> 9 <212> PRT <213> Artificial Sequence <400> 14 Ser Glu Leu Glu Ala Gly Asn Asp Phe 1 5 <210> 15 <211> 11 <212> PRT <213> Artificial Sequence <400> 15 Thr Asp Ile Leu Ala Asp Val Lys Thr Lys Arg 1 5 10 <210> 16 <211> 10 <212> PRT <213> Artificial Sequence <400> 16 Asp Ile Leu Ala Val Lys Thr Lys Arg Lys 1 5 10 <210> 17 <211> 10 <212> PRT <213> Artificial Sequence <400> 17 Leu Ser Glu Asp Gly Ala Gln Leu Leu Tyr 1 5 10 <210> 18 <211> 9 <212> PRT <213> Artificial Sequence <400> 18 Thr Pro Arg Pro Pro Gly Pro Gly Leu 1 5 <210> 19 <211> 9 <212> PRT <213> Artificial Sequence <400> 19 Down Down Down Down Down Down Down Down Down Down 1 5
Claims
1. A combination of antigenic peptides associated with breast cancer driver gene mutations, It is characterized in that The sequences of the antigen peptide combination associated with breast cancer driver gene mutations are SEQ ID NO.4, SEQ ID NO.7, SEQ ID NO.10, SEQ ID NO.13, SEQ ID NO.15 and SEQ ID NO.
17.
2. Application of an antigen peptide combination associated with breast cancer driver gene mutations, It is characterized in that The antigen peptide combination associated with breast cancer driver gene mutation as claimed in claim 1 is used to induce the production of specific cytotoxic T cell clones; the application is not for the purpose of diagnosis and treatment of the disease.
3. Application of an antigen peptide combination associated with breast cancer driver gene mutations, It is characterized in that The antigen peptide combination associated with breast cancer driver gene mutation as claimed in claim 1 is used to prepare a human immune activity regulator that can induce the production of specific cytotoxic T cell clones.
4. Application of an antigen peptide combination associated with breast cancer driver gene mutations, It is characterized in that The antigen peptide combination associated with breast cancer driver gene mutation as claimed in claim 1 is used to prepare a cell culture fluid for preventing and intervening in mutations of ESR1, GATA3, PALB2, SLC24A4, HA US3 and KMT2C genes.
5. Application of an antigen peptide combination associated with breast cancer driver gene mutations, It is characterized in that The antigen peptide combination associated with breast cancer driver gene mutation as claimed in claim 1 is used to prepare a breast cancer risk intervention therapeutic agent.
Citation Information
Patent Citations
Vaccines against an oncogenic isoform of ESR1 and methods of using the same
CA2954279A1
CDH1 mutation short peptide of tumor-associated gene and application thereof
CN109234283A
Compositions for treatment and diagnosis of breast cancer and methods for their use
CN1354791A
“peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers”
IN202048055447A
